Strengthening Pakistan’s API Manufacturing Base through Trade Remedies

On January 14, 2026, the National Tariff Commission of Pakistan (NTC) imposed definitive anti-dumping duties ranging from 8.61% to 11.81% on dumped imports of Cefadroxil originating from the People’s Republic of China, effective for five years from September 17, 2025.

This determination marks a significant milestone for Pakistan’s Active Pharmaceutical Ingredient (API) manufacturing sector, which has long faced pricing pressure from unfairly traded imports. By addressing dumping in a critical API, the decision supports domestic capacity utilization, investment continuity, and supply-chain resilience in the pharmaceutical value chain.

We were privileged to represent Pharmagen Limited, preparing and pursuing the anti-dumping application before the NTC. The outcome reflects the NTC’s acknowledgement of well-substantiated industry concerns and reinforces the role of trade remedies in nurturing a sustainable and competitive API ecosystem in Pakistan.

We remain committed to assisting domestic manufacturers in safeguarding fair competition and strengthening Pakistan’s pharmaceutical manufacturing base.

Notice of Final Determination